Navigation Links
Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV)
Date:7/16/2008

LOS ANGELES, July 16 /PRNewswire-FirstCall/ -- Vista Partners announced today that it has initiated coverage on MediciNova Inc. (Nasdaq: MNOV). "MediciNova has a promising drug development pipeline for treating a variety of diseases and conditions. The Company is primarily focused on two drug development programs; the first is MN-221 for the treatment of Status Asthmaticus. There are an estimated 2,000,000 visits to the emergency room a year for asthma related difficulties. The market for treatment of asthma related difficulties is in the billions and we believe MN-221, if approved, will garner a sizable percentage of the market potentially resulting in hundreds of millions of dollars in sales for MediciNova. The second drug in development is MN-166 for the treatment of multiple sclerosis (MS). MS is believed to affect approximately 350,000 to 400,000 people in the United States and over 2.5 million globally. Worldwide sales of drugs used in the treatment of MS were approximately $7.2 billion in 2006," said Ross Silver, Director of Research for Vista Partners. For more information and to download the report, please visit the Vista Partners website at http://www.vistap.com and click on the download research icon.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at

SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
3. Synvista Therapeutics to Present at the BIO InvestorForum 2007
4. Synvista Therapeutics to be Featured on Wallst.net
5. Provista Awards Agreement to Spheris
6. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
9. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
10. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
11. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... first quarter 2015 results before the Nasdaq market opens ... a live conference call and webcast to discuss its financial ... 30, 2015 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1906 (US) or 785-424-1825 (International) ...
(Date:4/23/2015)... , April 23, 2015  Cryoport, Inc. (OTCBB: ... logistics solutions for the life sciences industry, today ... cryogenic logistics solutions within the animal husbandry market ... Farms to support the shipment of equine semen ... horse Stallions. Animal husbandry is ...
(Date:4/23/2015)... Bethlehem, PA (PRWEB) April 23, 2015 ... announce it is the first EMC® Enterprise Content ... on the entire EMC Documentum® for Life ... Glemser has proven knowledge and capabilities to provide ... Documentum-based, purpose-built solutions. , The EMC Documentum ...
(Date:4/23/2015)... NEW YORK , April 23, 2015 /PRNewswire/ ... development stage healthcare company, focuses on the development ... colorectal cancer. The company lead product includes PRP, ... as trypsinogen and chymotrypsinogen, as well as the ... It is also developing a combination of anti-cancer ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Glemser Earns Accreditation for Life Sciences Solution Suite 2Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... , ATLANTA, Sept. 14 CryoLife, Inc. ... medical device and cardiovascular tissue processing company, announced today that it ... Conference at the Grand Hyatt New York in New York City. ... executive officer of CryoLife, Inc., will present Monday, September 21 at ...
... , NATICK, Mass., Sept. ... ) today announced that it has entered into a ... company offering advanced testing solutions for urinary incontinence. ... combines staffing, equipment, supplies and results analysis, helping to ...
... , HOLDEN, Mass., Sept. ... appointment of Elkan Gamzu, Ph.D. as Chairman to its ... years of pharmaceutical and biotechnology experience and has held ... President of Project Management at Millenium Pharmaceuticals, CEO of ...
Cached Biology Technology:CryoLife to Present at UBS Global Life Sciences Conference 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics' Board of Directors as Chair 2
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... September 2009) -- IEEE-USA President Gordon Day said today ... released by the White House and discussed by President ... Community College in Troy, N.Y. "IEEE-USA recognizes the ... plays in ensuring U.S. competitiveness, energy independence and national ...
... of Standards and Technology (NIST), in collaboration with ... a new reference material for beryllium. Beryllium, an ... high-performance alloys and ceramics, can cause berylliosisa chronic, ... material is expected to dramatically improve methods used ...
... The standard explanation for what causes Alzheimer,s is known as ... of an accumulation of the peptide amyloid beta, the toxic ... sticky plaques that have defined Alzheimer,s for more than 100 ... yearly targeting this toxic peptide but what if this ...
Cached Biology News:New beryllium reference material for occupational safety monitoring 2Rethinking Alzheimer's disease and its treatment targets 2Rethinking Alzheimer's disease and its treatment targets 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... Laminin-Based 96-well Cell Invasion Assay is designed ... using laminin as a significant barrier to ... in vitro in a convenient, high-throughput, 96-well ... appropriate for all types of adherent cells ...
... The GrabIt™ Kits are designed for the ... using a pull-down method. Proteins that interact ... fusion proteins are copurified using affinity ... are retained on a spin filter. The ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
Biology Products: